METHODS Medical records of patients who underwent CAS at Fortis Escorts Heart Institute and Research Center, since January 2015 were reviewed. We also maintained a prospective registry of all patients undergoing CAS at our hospital. Patients with CAS were selected for study if they satisfied following inclusion criteria: 1) Combined carotid and coronary artery disease; 2) Patients at high risk of CEA and having indication for CAS, (restenosis after CEA, contralateral carotid artery occlusion or laryngeal nerve palsy, bilateral carotid artery stenosis, previous radiation therapy or surgery on the neck, neck immobility, tracheostomy or tracheostoma, severe intracranial lesion, lesion inaccessible by surgery, advanced CAD example acute coronary syn- drome, three vessels disease or left main disease, heart failure, severe aortic stenosis, left ventricular ejection < 30%, renal failure, planned CABG or valve replacement, chronic obstructive pulmonary disease, cardiac and pulmonary disease, planned peripheral vascular surgery, myocardial infarction within 6 weeks of the procedure, age older than 80 years) 4) Adults>18 years 5) Carotid angiography showed carotid stenosis > 50% if symp- tomatic and >70% if asymptomatic. Exclusion criteria 1) Stroke / TIA / Amaurosis fugax within the past 14 days 2) Severely disabled as a result of stroke or dementia 3) Complete occlusion of carotid artery 4) Severe calcification, tortuosity of carotid artery 5) Intracranial tumor or cerebral venous malformation. The degree of stenosis was measured with duplex ultrasound scanning and arch aortography, according to the North American Asymptomatic Carotid Endarterectomy Trial (NASCET) method. Sta- tististical analysis was done using Mann Whitney test. All patients were seen by neurologist within 24 hrs after CAS, after 1 week and after 30 days. Patients were instructed to inform the coor- dinator (research nurse) or general practitioner if any symptoms possibly related to an ischemic event occurred after hospital discharge. Medical and nursing records were reviewed to determine nature and time of complications in the hospital and 30 days after CAS. RESULTS 44 (77.2%) patients were male. The mean age of patients was 65  8 years. 40 (71.9%) patients were neurologically asymp- tomatic. Symptomatic patient had predominant symptoms of chest pain, dyspnea, syncope/presyncope, dizziness, blurring of vision, paresis/paralysis. 47.4% patients had unilateral and 52.5% patients had bilateral carotid artery disease. Amongst all patients 59.6% had TVD, 17.5% had DVD, 14% had SVD & 8.8% patients had non-critical CAD. Among them 38.6% patients underwent PCI, 33.3% patients underwent surgery, 17.5% patients underwent both PCI and surgery and 10.6% patients were managed medically. Only 1 patient died after the procedure. Complications after CAS was seen in 10 patients: 1 patient had a stroke, 1 had shock, 6 patients had acute renal failure, 1 patient had infection and 1 patient had arrhythmia (Table2). One patient died. After discharge from the hospital, we followed all patients. Of all pa- tients 4 had a myocardial infarction, 1 patient had stroke (infarct) and 3 patients had worsening renal failure (Table3). There was no signif- icant difference between in-hospital complication and complication at one month after CAS. CONCLUSION Limitation. This is small registry with retrospective date to analyse. No randomized trial comparing different treatment strategies for concomitant carotid and coronary artery disease management has been conducted till date so thus far reported series are prone to selection/ reporting bias. In addition to the established surgical treatment (CEA- CABG, sequential/simultaneous), hybrid revascularization (CAS-CABG) is emerging as a viable therapeutic option. Larger, preferably multi- center, studies are required before this can become widely applied. We showed that for CAS EPD should be used to reduce complica- tions. No significant difference between complications during hospi- talization and within 30 days of CAS was seen. Severe combined carotid and coronary artery disease can be managed safely by hybrid approach. OTHER: CELL THERAPY AND ANGIOGENESIS (TCTAP A-054, TCTAP A-137) TCTAP A-054 The Study Endothelial Nitric Oxide Synthase Enzyme of EPC Colonies in the Coronary Atherosclerosis Sumiya Tserendavaa, 1 Odkhuu Enkhtaiwan, 1 Tsogtsaikhan Sandag, 1 Munkhzol Malchinkhuu 1 1 Mongolian National University of Medical Science, Mongolia BACKGROUND Endothelial progenitor cells (EPC) have a role in the maintenance and promotion of vascular repair and are negatively correlated with coronary atherosclerosis. In order to test this S30 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, VOL. 71, NO. 16, SUPPL S, 2018